Loading
A phase 2 trial of Evorpacept, Pembrolizumab, Cisplatin in head and neck squamous cell carcinoma, run by ALX Oncology Inc., active and no longer recruiting.
Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04) is a phase 2 interventional study registered as NCT04675333 by ALX Oncology Inc., with 172 participants enrolled, started 2021-05-10 and due to reach its primary completion in 2025-03-03. Interventions recorded: evorpacept, pembrolizumab, Cisplatin/Carboplatin; 5FU. Conditions listed: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
Shares ALX Oncology, Evorpacept, CD47 and SIRP-alpha blockade, Head and neck squamous cell carcinoma.
Shares ALX Oncology, Evorpacept, CD47 and SIRP-alpha blockade.
Shares ALX Oncology, Evorpacept, CD47 and SIRP-alpha blockade.
Shares Fluorouracil (5-FU), Cisplatin, Pembrolizumab, Immune checkpoint inhibitors.
Shares ALX Oncology, Evorpacept.
Shares Fluorouracil (5-FU), Cisplatin, Pembrolizumab.
Shares Fluorouracil (5-FU), Pembrolizumab, Immune checkpoint inhibitors.
Shares Fluorouracil (5-FU), Cisplatin, Pembrolizumab, Immune checkpoint inhibitors.